Robert Williams, DO
Cardiovascular Disease · Kalamazoo, MINPI 1730109778
Payments from drug & device makers
Across 775 payments — averaging $105.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$44K
- Bayer$17K
- Sanofi US Services Inc.$8K
- Novartis$5K
- Abbott$2K
- E.r. Squibb & Sons, L.L.C.$1K
- plus $6K from 31 others
What the payments were for
- Consulting fees$13,95026%
- Speaking & faculty fees$26,45049%
- Travel & lodging$1,5003%
- Food & beverage$12,38423%
- Education$750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 110 | $43,504 |
| Bayer | 10 | $16,959 |
| Sanofi US Services Inc. | 4 | $7,692 |
| Novartis | 116 | $4,548 |
| Abbott | 47 | $2,037 |
| E.r. Squibb & Sons, L.L.C. | 95 | $1,323 |
| Johnson & Johnson | 98 | $1,022 |
| Boston Scientific | 68 | $928 |
| Pfizer | 57 | $713 |
| Amgen | 34 | $521 |
| Amarin Pharma, Inc. | 26 | $360 |
| Boehringer Ingelheim | 17 | $332 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 21 | $311 |
| Inspire Medical Systems, Inc. | 4 | $172 |
| Medtronic(2 entities) | 4 | $163 |
| Regeneron Healthcare Solutions, Inc. | 8 | $134 |
| Daiichi Sankyo Inc. | 7 | $127 |
| Novo Nordisk | 6 | $115 |
| Scpharmaceuticals Inc. | 6 | $104 |
| Alnylam Pharmaceuticals Inc. | 4 | $88 |
| Kiniksa Pharmaceuticals, Ltd. | 4 | $68 |
| Kowa Pharmaceuticals America, Inc. | 4 | $65 |
| Kestra Medical Technology Services, Inc. | 3 | $62 |
| Travere Therapeutics, Inc. | 1 | $59 |
| Merck | 3 | $52 |
| Philips North America LLC | 2 | $47 |
| Lexicon Pharmaceuticals, Inc. | 3 | $47 |
| Edwards Lifesciences | 1 | $41 |
| Arbor Pharmaceuticals, Inc. | 1 | $39 |
| Bridgebio Pharma, Inc. | 2 | $37 |
| Sanofi-aventis U.S. LLC | 2 | $35 |
| Actelion Pharmaceuticals US, Inc. | 2 | $29 |
| Cordis US CORP. | 1 | $16 |
| Gilead | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Livanova USA, Inc. | 1 | $14 |
| Abiomed | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LOKELMA$41,669
- Cardiac Mapping System$740
- Quadra Assura CRT Defibrillator$173
- ENTRESTO$124
- JOT DX$119
- CoreValve Evolut$114
- CAMZYOS$111
How this compares
$81,809 in reported general payments places this provider in the 85th percentile of 760 cardiovascular disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 961 | $852,028 |
| CamzyosMavacamten | 39 | $325,463 |
| XareltoRivaroxaban | 284 | $318,638 |
| EntrestoSacubitril/Valsartan | 222 | $232,809 |
| Repatha SureclickEvolocumab | 111 | $112,130 |
| JardianceEmpagliflozin | 84 | $84,767 |
| FarxigaDapagliflozin Propanediol | 61 | $45,431 |
| BrilintaTicagrelor | 47 | $33,031 |
| Praluent PenAlirocumab | 34 | $30,017 |
| CorlanorIvabradine Hcl | 11 | $18,254 |
| Metoprolol Succinate | 815 | $15,197 |
| Flecainide Acetate | 163 | $9,584 |
| Ranolazine ErRanolazine | 87 | $7,404 |
| Amiodarone Hcl | 216 | $5,466 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 314 | $4,708 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $713 | $852,028961 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $1,323 | $325,46339 claims |
| Johnson & JohnsonXarelto | $1,022 | $318,638284 claims |
| NovartisEntresto | $4,548 | $232,809222 claims |
| Boehringer IngelheimJardiance | $332 | $84,76784 claims |
| AstraZenecaFarxiga, Brilinta | $43,504 | $78,462108 claims |
| AmgenCorlanor | $521 | $18,25411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 760 cardiovascular disease providers in Michigan.
Other cardiovascular disease in Kalamazoo
- Stanley ChetcutiAnn Arbor$4.3M
- Sandeep KhuranaGrandville$2.3M
- Victor MolesAnn Arbor$2.1M
- Jihad MustaphaGrand Rapids$1.9M
- Marschall RungeAnn Arbor$1.8M
- Sara SaberiAnn Arbor$1.6M
- Brian OneillDetroit$1.4M
- Vallerie McLaughlinAnn Arbor$1.4M
- Ahmad MizyedYpsilanti$1M
- Waleed DoghmiMidland$968K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.